Objectives: Ankylosing spondylitis (AS) is a chronic, progressive immune-mediated inflammatory disease, driven primarily by Th1 and Th17 cells. Anti-TNF therapies are successfully used in AS to achieve and maintain remission. However, their influence on the composition of T-cell subsets is not clear. We aimed to characterize the changes in the T-cell repertoire after a long-term anti-TNF treatment in AS patients. Methods: Twenty-two AS patients under long-term anti-TNF therapy were evaluated (15 anti-TNF responders and 7 nonresponders). A wide range of cell subtypes was analyzed with flow cytometry and compared with therapy-naïve and short-term data too. Results: Key findings include decreased proportions of naïve CD4 and CD8 cells, increased frequencies of Th1 and Th17 cells and higher Th1/Th2 ratios in the long-term anti-TNF-treated patients (responders, nonresponders and total), which was found to be significant not only when compared with healthy controls, but also with therapy-naïve and short-term anti-TNF-treated AS patients.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease, characterized by the coexistence of chronic, progressive inflammation of the axial skeleton (spondylitis) and peripheral joints and of new bone formation that eventually leads to ankylosis [1, 2] . The pathogenesis of AS has still remained only partly explored, but a strong association with the MHC class I al-lele HLA-B27 [3] and a perpetual activation of both the innate and the adaptive immune systems, in particular of the IL-23/IL-17 axis and of Th1 effector T-cell lineage with the overproduction of tumor necrosis factor-α (TNF-α), are considered to be key steps [4] .
Chronic hyperactivation of T lymphocytes and subsequent skewing of functional subgroups within CD4-and CD8-positive circulating T cells have been supported by some human studies. Analyses of the peripheral blood Tcell composition have revealed increased percentages of circulating Th17 helper lymphocytes [5] as well as increased numbers of Th2 cells [6] . On the other hand, regulatory T (T reg ) cells display decreased prevalence in the blood of AS patients suggesting that their lack may contribute to the pathogenesis of the disease [7] . The balance of Th17 and T reg cells has a major impact on T-cell activities during inflammatory rheumatic diseases, such as AS [8] . TNF-α induces the production of IL-17 and has an impact on the differentiation and activation of various T-cell subtypes, and therefore it has a significant role in shaping the adaptive immune system [9] . In view of the cardinal role of T cells in host defense, antitumor surveillance and immune homeostasis, it is, therefore, important to know how the composition of the T-cell repertoire is skewed during TNF blocker therapies, since these agents are usually applied for several years. There are only few studies addressing the question of how TNF inhibitors influence the T-cell repertoire in AS [10] [11] [12] [13] [14] . Most of the existing examinations, however, have operated with only few T-cell subsets [10] , and some of them examined only the role of T reg and/or Th17 cells [11, 12, 15] . The available articles do not make a distinction between peripheral and/or axial AS, and they use non-radiographic spondyloarthritis as an early stage of AS [10, 13] rather than as an individually existing entity. The applied medication is often missing from the cohort descriptions. Importantly, only 1 study analyzed patients with relatively long-standing anti-TNF treatment (6 months) [11] , whereas 2 further investigations, including our previous work, followed the T-cell repertoire only for a short time (6 weeks) [12, 14] , although we have recently demonstrated in our study of rheumatoid arthritis (RA) patients that there are profound differences in the T-cell subset distribution after short-term or long-term follow-up [16] .
Since TNF blockers must be used for several years in most of the patients with AS because the symptoms would recur in the vast majority of patients if the drug is stopped, it is important to know the type and degree of the alterations in the immune system developing during the long term, even several years of continuous anti-TNF therapy.
The aim of our comprehensive study is to give a welldescribed pathogenic overview of various T-cell subsets in AS before and during short-and long-term anti-TNF therapy, as we did in our previous work in this field in RA [16] . We intended to examine whether there is a difference between anti-TNF responder and anti-TNF nonresponder AS patients as well, and we compare the longterm anti-TNF-treated AS patients (more than 6 months) with our previous data on therapy-naïve and short-term (6 weeks) anti-TNF-treated AS patients too.
Patients and Methods

Study Population
Long-Term Anti-TNF-Treated AS Patients Twenty-two long-term anti-TNF-treated AS patients were enrolled in this study. All of them are treated at the Department of Rheumatology and Immunology, University of Szeged. AS was classified according to the modified New York criteria [17] . All the patients had been treated with anti-TNF agents for at least 6 months (long-term). All AS patients were treated with the first TNF inhibitor in their patient history at the time of the clinical and laboratory assessment. We distinguished long-term anti-TNF responder (n = 15) and long-term anti-TNF nonresponder (n = 7) AS patients. For the definition of the therapeutic response, we used the ASAS 5/6 improvement criteria [18] , and for remission we followed the ASAS remission criteria set [19] . All the patients had to meet the ASAS criteria for responder or nonresponder status for at least 1 month prior to the inclusion. In the responder group, 6 patients received infliximab, 7 adalimumab, and 2 etanercept. In the nonresponder group, there were 3 infliximab-, 4 adalimumab-, 1 etanercept-, and 1 golimumab-treated AS patients.
Therapy-Naïve and Short-Term Anti-TNF-Treated AS Patients To compare the effects of long-term anti-TNF therapy with therapy-naïve cases and with short-term (2 and 6 weeks) anti-TNF treatment, we used the cohort described in detail in our previous work [14] .
We recorded the HLA-B27 status, the presence of peripheral arthritis (in addition to the axial involvement), enthesitis, uveitis, inflammatory bowel disease ever occurring during the course of the disease, the grade of sacroiliitis and the presence of AS-specific changes on the spine (syndesmophyte or bamboo spine) on X-ray, and smoking history in every AS patient. Parameters of disease activity including C-reactive protein, erythrocyte sedimentation rate, and Bath ankylosing spondylitis disease activity and functional indices (BASDAI and BASFI, respectively) were also registered.
Healthy Controls
The control group included 10 age-and gender-matched healthy volunteers (mean 42, range 29-59 years). All of them had a negative history of AS symptoms and a negative status upon detailed physical and laboratory examination. Flow Cytometry Measurements The measurement protocol was identical in all aspects to what we had used in our previous studies [14, 20] . Blood samples were taken at least 6 months after the initiation of anti-TNF therapy (long-term follow-up). The results were also compared with those of the samples taken just before starting anti-TNF therapy, when each of the patients was under NSAID therapy alone, then in weeks 2 and 6 after the initiation of anti-TNF therapy (short-term followup) [14] . Laboratory procedures were as follows: blood samples were taken in the laboratory unit of the Department of Rheumatology and Immunology. We used 15 ml of anticoagulated blood and separated the peripheral blood mononuclear cells by centrifugation with Ficoll-Paque (GE Healthcare Life Sciences, Pittsburgh, PA, USA). Peripheral blood mononuclear cells were frozen and kept at -80 ° C until analysis. After thawing, samples were washed twice with phosphate-buffered saline solution (pH 7.4). Fluorescent antibodies were used (Becton Dickinson, San Diego, CA, USA) for cell surface staining according to the manufacturer's manual.
Identified 
Statistical Methods
Data are presented as means ± SD or median (25th-75th percentiles) depending on their distribution. Clinical parameters between responder and nonresponder patients were compared with the Student t test (categorical variables) or χ 2 test (prevalence within groups). Cell subset prevalence values were compared among groups with analysis of variance or with the Kruskal-Wallis test, with the Bonferroni or Dunn tests for multiple comparisons, respectively. A p value <0.05 was taken as statistically significant.
Results
AS Patient Characteristics under Long-Term Anti-TNF Therapy
Anti-TNF responder and anti-TNF nonresponder AS patients did not differ in terms of age, disease duration, smoking status, prevalence of HLA-B27 positivity, presence of peripheral arthritis, or the occurrence of enthesitis, uveitis or inflammatory bowel disease. Patients in both groups had a similar radiographic severity of sacroiliitis or frequency of AS-specific radiological spinal abnormalities. Not surprisingly, anti-TNF nonresponders had significantly higher mean C-reactive protein, erythrocyte sedimentation rate, BASDAI and BASFI values ( Table 1) . 
The Composition of the T-Cell Repertoire of AS Patients under Long-Term Anti-TNF Therapy
Our detailed analysis of the T-cell phenotypes of AS patients under long-term anti-TNF therapies is presented in Figures 1 and 2 , and numerically in Table 2 . Major findings are that all anti-TNF-treated AS patients (both anti-TNF nonresponders and anti-TNF responders) show a significantly lower prevalence of naïve CD4+ and CD8+ cells (CD4CD45RA+ and CD8CD45RA+), and higher frequencies of Th1 and Th17 cells, and Th17/T reg ratios than healthy controls. The proportion of T reg cells was similar to that in the controls. The prevalence of Numbers indicate mean ± SD values within the whole T-cell population (CD4 and CD8) or within CD4 cells (Th1, Th2, Th17, T reg and ratios), or for the other markers within the CD4 or CD8 cells, as indicated. a p < 0.05 versus anti-TNF nonresponder; b p < 0.05 versus anti-TNF responder. T cells with the late activation marker (CD4HLADR and CD8HLADR) was higher, and of T cells with the intermediate activation marker (CD4CD25) it was lower, and the Th1/Th2 ratio was higher only in the anti-TNF responders compared to the controls. Some differences were also revealed between the 2 AS patient groups: in anti-TNF responders, the frequencies of naïve CD4+ and CD8+ cells (CD4CD45RA+ and CD8CD45RA+) and of early activated CD8CD69 cells were lower than in anti-TNF nonresponders.
Comparison of the T-Cell Phenotype of AS Patients under Long-Term and Short-Term Anti-TNF Therapy
Since we had a database on the early changes in the Tcell repertoire in a cohort of anti-TNF-treated AS patients [14] , we had the opportunity to compare these data with our present results. T-cell subset prevalence in AS patients at the time of the initiation of anti-TNF therapy, 2 and 6 weeks thereafter (short-term) and after a long-term follow-up (at least 6 months after initiation of anti-TNF therapy) can be seen in Figures 3 and 4 . In summary, the decrease in the proportion of naïve CD4+ and CD8+ cells (CD4CD45RA and CD8CD45RA), and the increase in that of Th1, Th17 and T reg cells, and in Th1/Th2 ratios in the long-term anti-TNF-treated AS patients (responders, nonresponders, and total) has proven to be significant not only when compared with the controls (see above), but also with therapy-naïve and short-term anti-TNFtreated AS patients. Alterations within the various activated T-cell subsets -including increase in CD4HLADR-positive cells in responders, and in CD8HLADR-and CD4CD25-positive cells in the whole long-term treated AS group and in responders -have also become evident only after long-term anti-TNF therapy. 
Discussion
Anti-TNF therapy has revolutionized the treatment of immune-mediated rheumatic diseases including AS. The effect of cytokine neutralization as a driving force for the inhibition of inflammation is well exemplified by the use of TNF-α antibodies for the treatment of AS too. However, the knowledge of further influences of TNF inhibitors either on the cellular components of the immune system or their impact on intracellular T-or B-cell signaling is limited.
According to our best knowledge, the present results are the first in the literature that describe the composition of the T-cell repertoire in AS patients treated with anti-TNF agents for a sufficiently long period and with a wide range of cell subtype markers allowing a comprehensive overview of the adaptive immune system.
Conclusions of our results are: 1. several subtypes that reflect an activation state of the immune system, including Th17, Th1 cells and Th1/Th2 ratios, increased significantly during anti-TNF therapy, and the proportions of cells with various activation markers are also increased in AS as compared with healthy individuals, 2. the parallel compensatory increase in T reg cells was noted during long-term anti-TNF therapy in AS, 3. there are strikingly low proportions of naïve T cells (CD4CD45RA and CD8CD45RA) following long-term anti-TNF therapy in AS, 4. the impact of short-term and long-term anti-TNF therapy is different on T-cell phenotypes in AS, as most of the changes develop after more than 6 weeks of therapy, and 5. these differences exist also between short-term and long-term responders, which suggests that factors other than T-cell composition are responsible for the decrease in the clinical activity signs of AS.
There are many similarities in these results and our previous observations in RA patients [16] . The present measurements confirm our previous conclusions that the major mechanism of action of anti-TNF therapy is not the restoration of the activated immune system -observed in active disease -to a state similar to healthy individuals, in terms of the T-cell subset distribution. Rather, some key pathogenic processes, such as Th17 and, to a lesser extent, Th1 predominance in AS, seem to prevail although the inflammatory process has been put to quiescence clinically and also as reflected by routine laboratory inflammatory markers. Another consequent finding is the marked reduction of naïve T cells, both in the CD4+ and the CD8+ compartments. This finding has 2 potential explanations: (1) emigration of T-cell precursors from the thymus or release of naïve T cells from the secondary lymphoid organs is impaired, or (2) differentiation of memory T cells from naïve cells is accelerated. We propose the second explanation to be correct because the absolute number of T cells or the proportion of any other T-cell subsets is not decreased, and the permanent increase in the Th17 and Th1 subtypes, mainly the 2 activated subtypes that are the key drivers of inflammation in AS, suggest that the generation of newly differentiated effector T cells remains an ongoing process despite TNF blockers.
It may be of relevance that some of these changes (in particular, the decrease in CD4 and CD8 naïve T-cell frequencies and the elevation of Th1 proportions) were significantly more pronounced in anti-TNF responders than in nonresponders. In this regard, Chen et al. [21] have found that the percentage of Th17 cells and the serum concentration of IL-17 were higher in RA patients who subsequently became anti-TNF nonresponders, and in these patients these values even increased during the first 4 weeks of infliximab therapy. Furthermore, low Th17 cell frequencies predicted a good European League against Rheumatism response to anticytokine (including anti-TNF) therapies, whereas high CD24 hi CD27+ B reg prevalences were predictors to response to abatacept in RA [22] . We have revealed that low CD4CD69 cell frequency at the initiation of anti-TNF therapy was a good predictor of treatment response to anti-TNF treatment in RA [16] . However, data are much scarcer in relation to AS, in which an increase in Th17 cell frequencies has also been revealed during anti-TNF treatment [12] , but opposing results have also been obtained by others [11] . Prospective examination of T-cell subset distribution in a larger number of AS patients could help answer the question of whether these proinflammatory T-cell subsets or other T-cell subtypes may be associated with therapy resistance or may contribute to disease relapse after the withdrawal of anti-TNF treatment.
The expansion of Th17 and Th1 cells has been described by other authors too [23, 24] , and we observed a similar phenomenon in RA too [16] . A potential explanation has been presented by Notley et al. [25] , who have shown that anti-TNF treatment of mice in the collageninduced arthritis model led to the upregulation of the p40 subunit of the IL-12/23 receptor and a resulting increase in both Th17 and Th1 cell frequencies. They explained the reduction in collagen-induced arthritis activity in anti-TNF-treated mice with their observation that the amount of Th1 and Th17 cells in the synovium markedly decreased despite the expansion of these cells in the blood and lymph nodes of the animals. In RA patients, Th1 and Th17 cells and IL-17 production were found to increase during anti-TNF therapy, and it was independent of the clinical response [23] . However, CCR6 expression was significantly downregulated in Th17 cells of RA patients in remission under anti-TNF therapy as compared with those with active disease [23] . These findings further support that, in spite of the increased amount of the circulating proinflammatory T cells during anti-TNF therapy, the inactivity of the disease is maintained by alterations in various effector functions of these cells.
Rather, the clinically reflected inactivity of the inflammatory process is ensured by the sufficient number and effect of T reg cells, and the blockade of the key effector cytokines, in this case, of TNF-α. Furthermore, some intracellular signaling processes that are integral parts of lymphocyte activation are also altered in AS. These include intracellular nitric oxide and calcium handling, as we have described in our previous work. There are marked differences in the impact of short-and long-term anti-TNF therapy on these processes [14] . We think that it will be interesting to follow the T-cell repertoire in AS during Th17 blocker therapies (IL-23-or IL-17 inhibitors) and follow the long-term effects TNF blockers on intracellular signaling processes too.
The fact that the proportion of effector T-cell subtypes (Th1, Th17, and various activated T-cell subpopulations) does not decrease during anti-TNF therapy (in fact, they rather increase) may indicate that the T-cell repertoire necessary for an effective antitumor or antimicrobial defense is not compromised even after a substantial duration of anti-TNF therapy. This may provide a potential explanation to the findings from registry studies of large patient populations that the incidence of the vast majority of tumor types does not seem to increase even after several years of biological treatments, and, albeit with cautious infection surveillance and prevention, the inci- This study has several strengths and a few weak points at the same time. Advantages are the high number of Tcell subtypes measured simultaneously and the long-term follow-up, since the experience from our and others' studies indicates that several months are necessary until a new steady state in the T-cell repertoire develops during clinically effective biological therapies in AS. A limitation of this study is the comparison of partly different cohorts of short-term-and long-term treated AS patients. Since these 2 cohorts contain AS patients from the same geographical area, racial and gender composition, treated in the same center with identical diagnostic and therapeutic principles and agents, and the laboratory techniques were totally identical in all aspects for the measurements of both cohorts, we believe that the comparisons of AS patients with short-or long-term anti-TNF therapy sufficiently corroborate our conclusions.
